Lorus, NCI plan study of GTI-2040 in myelodysplastic syndrome, leukemia

By Lisa Kerner

Charlotte, N.C., June 19 - Lorus Therapeutics Inc. said The National Cancer Institute Cancer Therapies Evaluation Program is sponsoring a new clinical investigation of the antisense oligonucleotide GTI-2040 as a single-agent in patients with high-grade myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Patients with MDS that progresses to AML have been identified as an especially high-risk group for poor survival, according to a company news release.

"The extension of the GTI-2040 AML program to include MDS is consistent with the already announced priority focus by Lorus on GTI-2040 in AML," chief executive officer Jim Wright said in the release.

"This builds on our already ongoing clinical study of GTI-2040, for which data correlating complete responses with down regulation of R2, the molecular target of GTI-2040, has been presented in an AML salvage patient population."

Lorus is a Toronto-base biopharmaceutical company focused on the research and development of cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.